Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial

Eur Respir J. 2024 Sep 12;64(3):2401368. doi: 10.1183/13993003.01368-2024. Print 2024 Sep.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial* / drug therapy
  • Male
  • Middle Aged
  • Mycophenolic Acid* / therapeutic use
  • Rituximab* / therapeutic use
  • Treatment Outcome

Substances

  • Mycophenolic Acid
  • Rituximab
  • Immunosuppressive Agents